NCT06388135View on ClinicalTrials.gov

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Serplulimab Combined With Nab-paclitaxel and Cisplatin

Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.

DRUG

nab-paclitaxel，Cisplatin

nab-paclitaxel，Cisplatin

All Listed Sponsors
lead

Yang Jianjun, PhD

OTHER

NCT06388135 - Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter